|Bid||61.01 x 800|
|Ask||62.21 x 800|
|Day's Range||60.28 - 61.43|
|52 Week Range||58.29 - 74.29|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||1.16|
|Expense Ratio (net)||0.57%|
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
Pharmaceutical sector-related ETFs stood out Thursday after Horizon Pharma (HZNP) revealed positive test results for its treatment of thyroid eye disease, or TED. Among the better performing non-leveraged ETFs of Thursday, the First Trust Nasdaq Pharmaceuticals ETF (FTXH) rose 1.8%, Invesco Dynamic Pharmaceuticals ETF (PJP) gained 1.5% and SPDR Pharmaceuticals ETF (XPH) increased 2.3%. Horizon Pharma shares surged 32.5% Thursday following the release of positive test results in its Phase 3 trial of its thyroid eye disease drug, teprotumumab, TheStreet reports.
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Bausch Health (BHC) generated revenues of $2.1 billion in the third quarter of this year compared to $2 billion in the third quarter of 2017, a ~4% YoY decline. Bausch Health generated revenues of $6.26 billion over the first nine months of this year compared to $6.56 billion in the same period the prior year, reflecting a ~5% YoY decline.
Investors should focus on some strategies as to which sector should they take positions or which should be avoided if bipartisan government forms.
With a contentious midterms election season coming up, many anticipate a split government that could potentially impact the way ETF investors ride the markets ahead. Some expectations point to Democrats winning back the House of Representatives and the Republicans maintaining a narrow hold on the Senate - Republicans currently dominate both chambers. "If the consensus expectation of a divided government turns out to be correct, the most likely political consequences would be an increase in investigations and uncertainty surrounding fiscal deadlines," David Kostin, Goldman's chief U.S. equity strategist, said in a note.
Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.
The healthcare sector will continue to see political attention in the remainder of 2018, with the 2017 U.S. tax reform bill influencing it in a number of ways. Its repeal of mandated healthcare is likely to change demand and effect provider participation.
In this article, we’ll discuss several major ETFs in the pharmaceuticals sector and their third-quarter returns. The chart below compares the market capitalization of these pharmaceutical ETFs on October 3.
Eli Lilly and Company (LLY) reported a top line of $6.4 billion in the second quarter, a 9% YoY (year-over-year) rise in revenue compared to $5.8 billion in the second quarter of 2017.
On September 12, Allergan (AGN) announced the launch of SpotLyte, the first launch from Project Moonwalker, the Allergan-owned digital ventures unit. On September 6, Allergan announced the launch of its dual-acting product, the SkinMedica Lumivive System. SpotLyte is the first venture from Project Moonwalker and is designed to educate consumers on medical aesthetics.
Supernus Pharmaceuticals’ (SUPN) Trokendi XR generated revenues of $76.4 million in the second quarter, compared to $56.0 million in the second quarter of 2017, reflecting ~36.4% YoY (year-over-year) growth.
Pharmaceutical stocks and sector-related exchange traded funds have enjoyed a great summer and the rally may continue to have legs. Meanwhile, the broader iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) rose 10.6%. There were no clear catalysts to explain the rally as we did not witness any memorable earnings beats, new clinical trials or large-scale deals, the Wall Street Journal reports.
Investors are always looking for growth in small-cap stocks like Projprzem SA (WSE:PJP), with a market cap of zł115.47m. However, an important fact which most ignore is: how financially healthyRead More...
Pfizer (PFE) reported a rise in revenue in international markets during the second quarter. The Innovative Health segment reported a rise of 3% in revenue to ~$4.58 billion, while the Essential Health segment reported a ~14% fall in revenue to $1.65 billion. The rise in the Innovative Health segment was driven by a 5% rise in vaccines sales, a 5% rise in oncology sales, a 33% rise in inflammation and immunology sales, and a 1% rise in consumer healthcare sales.
The healthcare sector is the second-largest sector exposure in the S&P 500. This prominence is reflected in the world of exchange-traded funds (ETFs), where there are dozens of healthcare ETFs.